Glenmark to commercialize six SCD eye products in North America
South Korea’s Sam Chun Dang (SCD) Pharm has signed a 600 million won ($558,000) deal to license out a portfolio of six ophthalmic products to the US subsidiary of Indian drugmaker Glenmark Pharmaceuticals (BSE: 532296) for marketing the products in the USA and Canada.
Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America.
"The agreement for these ophthalmic products is aligned with our strategy to strengthen our focus on complex generic formulations," said Robert Matsuk, president, North America & Global API at Glenmark Pharmaceuticals, adding: "Our strategic partnership with SCD supports our objective to expand the product offerings of our complex generic portfolio."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze